Tuberculosis prevention in methadone maintenance clinics: Effectiveness and cost-effectiveness

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 1, 1999, Pages 178-185

  Snyder, David C ^a   Paz, E Antonio ^a   Mohle Boetani, Janet C ^a   Fallstad, Robert ^a   Black, Rosa Lee ^a   Chin, Daniel P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ARTICLE; COMMUNITY MEDICINE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SERODIAGNOSIS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNITED STATES;

EID: 0032787239     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.1.9810082     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. 1997. Tuberculosis morbidity: United States, 1996. MMWR Morb. Mortal. Wkly. Rep. 46:695-700.
2. Centers for Disease Control and Prevention. 1990. Screening for tuberculosis and tuberculous infection in high-risk populations. MMWR Morb. Mortal. Wkly. Rep. 39:1-12.
3. Centers for Disease Control and Prevention. 1989. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR Morb. Mortal. Wkly. Rep. 38:236-250.
4. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Friedland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545-550.
5. Selwyn, P. A., B. M. Sckell, P. Alcabes, G. H. Friedland, R. S. Klein, and E. E. Schoenbaum. 1992. High risk of active tuberculosis in HIV-seropositive drug users with cutaneous anergy. J.A.M.A. 268:504-509.
6. Antonucci, G., E. Girardi, M. C. Raviglione, and G. Ippolito. 1995. Risk factors for tuberculosis in HIV-seropositive persons: a prospective cohort study. J.A.M.A. 274:143-148.
7. Markowitz, N., N. Hansen, and P. C. Hopewell. 1997. Incidence of tuberculosis in the United States among HIV-seropositive persons. Ann. Intern. Med. 126:123-132.
8. Whalen, C., C. R. Horsburgh, D. Hom, C. Lahart, M. Simberkoff, and J. Ellner. 1995. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med. 151:129-135.
9. Leroy, V., L. R. Salmi, M. Dupon, A. Sentilhes, J. Texier-Maugein, L. Dequae, F. Dabis, and R. Salamon. 1997. Progression of human immunodeficiency virus infection in patients with tuberculosis disease: a cohort study in Bordeaux, France, 1988-1994. The Groupe d'Epidemiologic Clinique du Sida en Aquitaine (GECSA). Am. J. Epidemiol. 145:293-300.
10. 21 Code of Federal Regulations, Part 291, Section 291, 501.
11. Curtis, R., S. R. Friedman, A. Neagius, B. Jose, M. Goldstein, and D. C. Des Jarlais. 1994. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep. 109:319-327.
12. Centers for Disease Control. 1993. Tuberculosis prevention in drug-treatment centers and correctional facilities-selected U.S. sites, 1990-91. MMWR Morb. Mortal. Wkly. Rep. 42:210-213.
13. 42 Code of Federal Regulations. Part 2, Section 2.12, 2.13 (a).
14. American Thoracic Society. 1994. Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. 149:1359-1374.
15. SAS for Windows, release 6.12. SAS Institute Inc., Cary, NC.
16. Microsoft Excel for Windows 95, Version 7.0a., Microsoft Corporation, Redmond, WA.
17. Beck, J. R., and S. G. Pauker. 1983. The Markov Process in medical prognosis. Med. Decis. Making 3:419-458.
18. Daley, C. L., J. A. Hahn, A. R. Moss, P. C. Hopewell, and G. F. Schecter. 1998. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am. J. Respir. Crit. Care Med. 157:19-22.
19. Brown, R. E., B. Miller, W. R. Taylor, C. Palmer, L. Bosco, R. M. Nicola, J. Zelinger, and K. Simpson. 1995. Health care expenditures for tuberculosis in the United States. Arch. Intern. Med. 155:1595-1600.
20. Fallab-Stubi, C. L., J. P. Zellweger, A. Sauty, D. I. Uldry, and M. Burnier. 1998. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int. J. Tuberc. Lung. Dis. 2:525-530.
21. Gourevitch, M. N., W. Wasserman, M. Panero, and P. Arno. 1996. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J. Addict. Dis. 15:93-104.
22. Chaulk, C. P., and V. A. Kazandijian. 1998. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. J.A.M.A. 279: 943-948.
23. Burman, W. J., R. R. Reves, A. P. Hawkes, C. A. Rietmeijer, Z. Yang, H. El-Hajj, J. H. Bates, and M. D. Cave. 1997. DNA fingerprinting with two probes decreases clustering of Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 155:1140-1146.
24. Genewein, A., A. Telenti, C. Bernasconi, C. Mordasini, S. Weiss, A. M. Maurer, H. L. Reider, K. Schopfer, and T. Bodmer. 1993. Molecular approaches to identifying route of transmission of tuberculosis in the community. Lancet 342:841-844.
25. Cayla, J. A., P. Garcia De Olalla, H. Galdos-Tanguis, R. Vidal, J. L. Lopez-Colomes, J. M. Gatell, and J. M. Jansas. 1996. The influence of intravenous drug use and HIV infection in the transmission of tuberculosis. AIDS 10:95-100.
26. Friedman, C. R., G. C. Quinn, B. N. Kreiswirth, D. C. Perlman, N. Salomon, N. Schluger, M. Lutfey, J. Berger, N. Poltoratskaia, and L. W. Riley. 1997. Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J. Infect. Dis. 176:478-484.
27. Salpeter, S. R., G. D. Sanders, E. E. Salpeter, and D. K. Owens. 1997. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis, Ann. Intern. Med. 127::1051-1061.
28. Ferebee, S. H. 1970. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv. Tuberc. Res. 17:28-106.
29. Report of Verified Case of Tuberculosis, California Department of Health Services, Tuberculosis Control Branch, Sacramento, CA.
30. Jordan, T. J., E. M. Lewit, R. L. Montgomery, and L. B. Reichmann. 1991. Isoniazid as preventive therapy in HIV-seropositive intravenous drug abusers. J.A.M.A. 265:2987-2991.
31. National Center for Health Statistics. 1994. Vital Statistics of the United States, 1990. U.S. Department of Health and Human Services, Bethesda, MD.
32. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull. World Health Organ. 1982, 4:555-564.
33. Petiti, D. B. 1994. Meta-Analysis, Decision Analysis and Cost Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. Oxford University Press.
34. Beck, J. R., J. P. Kassirer, and S. G. Pauker. 1982. A convenient approximation of life expectancy (the "DEALE"). Am. J. Med. 73:883-888.